GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » PEG Ratio

CPP (Cancer Prevention Pharmaceuticals) PEG Ratio : N/A (As of Jun. 13, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Cancer Prevention Pharmaceuticals's PE Ratio without NRI is 0.00. Cancer Prevention Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, Cancer Prevention Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Cancer Prevention Pharmaceuticals's PEG Ratio or its related term are showing as below:



CPP's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Cancer Prevention Pharmaceuticals PEG Ratio Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals PEG Ratio Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
PEG Ratio
- - -

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
PEG Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of Cancer Prevention Pharmaceuticals's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's PEG Ratio falls into.


;
;

Cancer Prevention Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Cancer Prevention Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Cancer Prevention Pharmaceuticals  (AMEX:CPP) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Cancer Prevention Pharmaceuticals PEG Ratio Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals Headlines